PCR Hemophilia-A Inversion panel (Intron 22 & 1):
Hemophilia A is a hereditary bleeding disorder caused by abnormalities in the F8 gene, which is responsible for producing Factor VIII, a vital clotting protein required for normal blood coagulation. When this clotting factor is absent or defective, the body struggles to stop bleeding efficiently, leading to prolonged bleeding episodes, spontaneous internal hemorrhage, and repeated joint or muscle bleeding that may result in long-term complications. Among the many genetic changes associated with Hemophilia A, intron 22 and intron 1 inversions are considered some of the most common causes of severe disease forms. The PCR Hemophilia-A Inversion Panel (Intron 22 & 1) is a highly focused molecular diagnostic test specifically developed to identify these important genetic rearrangements within the F8 gene. Using advanced Polymerase Chain Reaction technology, the test accurately detects inversion mutations that may not be identified through routine clotting studies alone. This analysis is extremely valuable for patients experiencing unexplained bleeding symptoms, individuals with confirmed low Factor VIII activity, and families with a known history of Hemophilia A.
What is the PCR Hemophilia-A Inversion Panel (Intron 22 & 1)?
The PCR Hemophilia-A Inversion Panel is a specialized genetic test developed to identify intron 22 and intron 1 inversions within the F8 gene, which are among the most common mutations associated with severe Hemophilia A. These inversions interfere with the normal production of Factor VIII, an important clotting protein required for proper blood coagulation. The test uses advanced PCR-based molecular techniques to detect these specific genetic rearrangements accurately. This analysis is extremely useful for confirming the genetic basis of Hemophilia A in patients experiencing abnormal bleeding symptoms, repeated bruising, or prolonged clotting times. Identifying these inversions also supports treatment planning, family screening, and genetic counseling for affected families.
Why are intron 22 and intron 1 inversions important in Hemophilia A?
Intron 22 and intron 1 inversions are significant because they account for a large proportion of severe Hemophilia A cases worldwide. These genetic alterations disrupt the structure of the F8 gene, preventing the body from producing functional Factor VIII protein. Individuals carrying these inversions often experience serious bleeding complications beginning in childhood. Detecting these mutations provides valuable information regarding disease severity and helps physicians understand the underlying cause of the disorder. Because these inversions are relatively common in severe Hemophilia A, testing for them is considered an essential component of genetic diagnosis.
What is the cost of the PCR Hemophilia-A Inversion Panel?
The cost of the PCR Hemophilia-A Inversion Panel (Intron 22 & 1) is ₹18,200. This pricing includes detailed molecular analysis for detecting intron 22 and intron 1 inversions associated with severe Hemophilia A. Since the test involves specialized PCR-based genetic evaluation and expert interpretation, it provides highly valuable diagnostic information for affected individuals and their families.
Who should undergo this PCR inversion panel test?
This PCR Hemophilia-A Inversion Panel test is recommended for individuals suspected of having Hemophilia A, especially those with severe bleeding symptoms or low Factor VIII activity levels. Patients with a family history of Hemophilia A may also benefit from this genetic analysis to identify inherited mutations. Women with a known family history of the disorder often choose testing to determine carrier status before pregnancy. Children showing excessive bruising, recurrent joint bleeding, or unusual bleeding after injuries may also require this evaluation. Early testing helps families receive timely diagnosis and appropriate medical guidance.
How accurate is the PCR inversion panel?
The PCR Hemophilia-A Inversion Panel is considered highly accurate for detecting intron 22 and intron 1 inversions in the F8 gene. Advanced PCR-based molecular methods provide dependable identification of these structural rearrangements, which are frequently associated with severe Hemophilia A. The use of targeted genetic analysis increases diagnostic reliability and supports confident clinical interpretation. Accurate mutation detection is extremely important because treatment decisions and family counseling often depend on the findings.
How does the PCR inversion test work?
The PCR Hemophilia-A Inversion Panel works by analyzing DNA extracted from a blood sample. Specialized molecular techniques are used to identify structural rearrangements involving intron 22 and intron 1 regions of the F8 gene. Polymerase Chain Reaction technology amplifies targeted sections of DNA, allowing laboratory specialists to detect abnormal inversion patterns accurately. The testing process is highly sensitive and provides reliable results for confirming severe Hemophilia A-associated mutations. This advanced molecular approach helps improve diagnostic precision compared to routine clotting studies alone.
What symptoms may indicate the need for this test?
Individuals who experience prolonged bleeding after cuts, dental procedures, surgeries, or injuries may require this test. Frequent bruising, recurrent nosebleeds, swelling in joints caused by internal bleeding, and delayed clot formation are also common warning signs. Severe Hemophilia A may cause spontaneous bleeding episodes without obvious trauma, particularly in muscles and joints. Children with unexplained bruises or painful swollen joints should be evaluated carefully because early symptoms may indicate an inherited clotting disorder requiring genetic confirmation.
Can this test confirm Hemophilia A diagnosis?
Yes, this inversion panel can strongly support the diagnosis of Hemophilia A by identifying specific disease-causing mutations within the F8 gene. While routine clotting factor testing may show reduced Factor VIII activity, genetic analysis helps confirm the exact molecular defect responsible for the condition. Detecting intron 22 or intron 1 inversions provides a clearer understanding of the genetic basis of severe Hemophilia A and assists physicians in planning appropriate long-term management strategies.
Is this test useful for carrier screening?
Yes, the PCR Hemophilia-A Inversion Panel is valuable for carrier screening in women with a family history of Hemophilia A. Female carriers may pass the altered F8 gene to their children even if they have mild or no symptoms themselves. Identifying carrier status helps families understand inheritance risks and supports informed reproductive planning. Carrier testing also allows women to receive proper medical monitoring during pregnancy and childbirth, especially if clotting factor levels are reduced.
Is fasting required before the test?
Fasting is generally not required before undergoing the PCR Hemophilia-A Inversion Panel. Patients can usually continue their normal diet and daily activities before sample collection unless specific instructions are provided by the healthcare provider. However, patients should inform the laboratory about recent blood transfusions or clotting factor treatments, as these details may assist clinicians in correlating genetic findings with clinical symptoms and laboratory history.
Why is early diagnosis important in Hemophilia A?
Early diagnosis helps reduce the risk of severe bleeding complications that may damage joints, muscles, and internal organs over time. Repeated bleeding into joints can cause chronic pain, swelling, and permanent mobility issues if not managed properly. Identifying the condition early allows doctors to begin preventive treatment and educate families regarding bleeding precautions, physical activity safety, and emergency management strategies. Timely diagnosis significantly improves long-term health outcomes and quality of life.
Can Hemophilia A occur without family history?
Yes, some individuals develop Hemophilia A due to spontaneous genetic mutations even when there is no known family history of the disorder. These newly developed mutations may arise during early development and later become hereditary in future generations. Because spontaneous mutations can produce severe symptoms unexpectedly, genetic testing becomes essential for confirming diagnosis and identifying the specific abnormality within the F8 gene.
What role does Factor VIII play in blood clotting?
Factor VIII is a crucial clotting protein involved in the coagulation cascade that helps stop bleeding after blood vessel injury. When Factor VIII levels are severely reduced or dysfunctional, the body cannot form stable blood clots effectively. This results in prolonged bleeding episodes, internal hemorrhage, and difficulty controlling bleeding after injuries or surgeries. Mutations involving intron 22 and intron 1 inversions interfere with the production of normal Factor VIII, leading to severe Hemophilia A symptoms.
What are the benefits of PCR-based genetic testing?
PCR-based genetic testing offers highly sensitive and precise mutation detection using advanced molecular techniques. The method allows laboratories to identify specific genetic inversions that may not be visible through routine laboratory evaluation alone. PCR analysis is efficient, dependable, and widely used in modern molecular diagnostics because of its accuracy and ability to provide targeted genetic information. This technology greatly improves the diagnostic process for inherited bleeding disorders like Hemophilia A.
Can this test influence treatment decisions?
Yes, identifying intron 22 or intron 1 inversions can help physicians better understand disease severity and create personalized treatment plans for affected individuals. Certain genetic mutations are associated with a higher risk of complications such as inhibitor development during clotting factor therapy. Knowing the exact mutation helps doctors monitor patients more carefully and adjust treatment strategies according to clinical needs and bleeding patterns.
Are the test reports confidential?
Yes, patient confidentiality is maintained throughout the testing process. Genetic reports are usually shared only with authorized healthcare professionals or individuals approved by the patient. Reputable diagnostic laboratories follow strict privacy policies and secure data management procedures to protect sensitive medical and genetic information from unauthorized access.
Why should patients choose the PCR Hemophilia-A Inversion Panel?
The PCR Hemophilia-A Inversion Panel provides targeted genetic evaluation for detecting some of the most important mutations linked to severe Hemophilia A. By specifically identifying intron 22 and intron 1 inversions, the test offers valuable diagnostic clarity that supports accurate disease confirmation, treatment planning, and family risk assessment. Early and reliable genetic identification helps reduce complications, improve patient care, and guide families toward informed healthcare decisions. With advanced molecular analysis and expert interpretation, this specialized test plays an essential role in the comprehensive management of inherited bleeding disorders.
How long does it take to receive the results?
The turnaround time for the PCR Hemophilia-A Inversion Panel (Intron 22 & 1) is usually around 25 to 30 days. This timeframe allows detailed molecular testing and careful analysis to ensure accurate and dependable genetic reporting.
Conclusion:
The PCR Hemophilia-A Inversion Panel (Intron 22 & 1) serves as an important genetic diagnostic tool for identifying major inversion mutations linked to severe Hemophilia A. By specifically targeting intron 22 and intron 1 abnormalities within the F8 gene, this advanced molecular test provides accurate confirmation of inherited clotting disorders and supports a deeper understanding of the genetic basis of the disease. Reliable mutation detection helps physicians develop more personalized treatment and monitoring plans while also assisting families in understanding inheritance patterns and future reproductive risks. Early identification of these inversions can significantly reduce complications associated with delayed diagnosis, including chronic joint damage, repeated internal bleeding, and long-term physical limitations.
